Oral nefopam and aspirin

Area of Science:

• Pharmacology
• Pain Management
• Clinical Trials

Background:

• Moderate to severe somatic pain, including postoperative and fracture pain, presents a significant clinical challenge.
• Effective and safe analgesics are crucial for patient recovery and well-being.

Purpose of the Study:

• To compare the analgesic efficacy of nefopam and aspirin against a placebo in hospitalized patients.
• To establish the dose-response relationship and relative potency of nefopam compared to aspirin.

Main Methods:

• A double-blind, noncrossover study involving 122 hospitalized patients with moderate to severe pain.
• Patients received varying doses of nefopam (30 mg, 60 mg, 90 mg), aspirin (325 mg, 650 mg), or placebo.
• Pain intensity and relief were assessed over a 6-hour period using sum of pain intensity differences (SPID) scores.

Main Results:

• Both nefopam and aspirin showed consistent dose-dependent analgesic effects compared to placebo.
• The estimated relative potency of nefopam to aspirin was 10.4 (95% CI: 6.3–20.8) for SPID.
• Nefopam 60 mg was found to be equivalent in analgesic potency to aspirin 650 mg.
• Reported side effects were minimal for both active medications.

Conclusions:

• Nefopam is an effective analgesic for moderate to severe somatic pain, with a potency comparable to aspirin.
• The findings support the use of nefopam as a viable option for pain management, offering a favorable efficacy and safety profile.
• Further research may explore nefopam's role in various pain conditions and patient populations.